JP2013525801A5 - - Google Patents

Download PDF

Info

Publication number
JP2013525801A5
JP2013525801A5 JP2013508294A JP2013508294A JP2013525801A5 JP 2013525801 A5 JP2013525801 A5 JP 2013525801A5 JP 2013508294 A JP2013508294 A JP 2013508294A JP 2013508294 A JP2013508294 A JP 2013508294A JP 2013525801 A5 JP2013525801 A5 JP 2013525801A5
Authority
JP
Japan
Prior art keywords
daltons
autism
cellular
signature
metabolite
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013508294A
Other languages
English (en)
Japanese (ja)
Other versions
JP6021187B2 (ja
JP2013525801A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/034654 external-priority patent/WO2011139914A1/en
Publication of JP2013525801A publication Critical patent/JP2013525801A/ja
Publication of JP2013525801A5 publication Critical patent/JP2013525801A5/ja
Application granted granted Critical
Publication of JP6021187B2 publication Critical patent/JP6021187B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013508294A 2010-04-29 2011-04-29 自閉症の代謝バイオマーカー Expired - Fee Related JP6021187B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32951510P 2010-04-29 2010-04-29
US61/329,515 2010-04-29
PCT/US2011/034654 WO2011139914A1 (en) 2010-04-29 2011-04-29 Metabolic biomarkers of autism

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015189529A Division JP2015231392A (ja) 2010-04-29 2015-09-28 自閉症の代謝バイオマーカー

Publications (3)

Publication Number Publication Date
JP2013525801A JP2013525801A (ja) 2013-06-20
JP2013525801A5 true JP2013525801A5 (2) 2014-05-22
JP6021187B2 JP6021187B2 (ja) 2016-11-09

Family

ID=44533446

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013508294A Expired - Fee Related JP6021187B2 (ja) 2010-04-29 2011-04-29 自閉症の代謝バイオマーカー
JP2015189529A Pending JP2015231392A (ja) 2010-04-29 2015-09-28 自閉症の代謝バイオマーカー

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015189529A Pending JP2015231392A (ja) 2010-04-29 2015-09-28 自閉症の代謝バイオマーカー

Country Status (6)

Country Link
US (2) US9547013B2 (2)
EP (1) EP2564194B1 (2)
JP (2) JP6021187B2 (2)
AU (2) AU2011248464B2 (2)
CA (1) CA2797787C (2)
WO (1) WO2011139914A1 (2)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101322695B1 (ko) * 2010-08-25 2013-10-25 주식회사 엘지화학 케이블형 이차전지
CA2813606C (en) 2010-10-07 2019-01-22 Sarkis K. Mazmanian Probiotic therapies for autism
WO2014036182A2 (en) 2012-08-29 2014-03-06 California Institute Of Technology Diagnosis and treatment of autism spectrum disorder
MX2016000293A (es) * 2013-07-09 2016-06-21 Stemina Biomarker Discovery Inc Biomarcadores del trastrono del espectro autista.
US20160209428A1 (en) * 2013-08-21 2016-07-21 The Regents Of The University Of California Diagnostic and predictive metabolite patterns for disorders affecting the brain and nervous system
EP3805756A1 (en) * 2014-04-08 2021-04-14 Metabolon, Inc. Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment
US20150294081A1 (en) 2014-04-11 2015-10-15 Synapdx Corporation Methods and systems for determining autism spectrum disorder risk
US9176113B1 (en) 2014-04-11 2015-11-03 Synapdx Corporation Methods and systems for determining autism spectrum disorder risk
CA2966360C (en) 2014-10-30 2023-09-05 California Institute Of Technology Compositions and methods comprising bacteria for improving behavior in neurodevelopmental disorders
WO2016069801A1 (en) 2014-10-30 2016-05-06 California Institute Of Technology Compositions and methods comprising bacteria for improving behavior in neurodecelopmental disorders
GB2556436B (en) 2015-03-06 2022-01-26 Micromass Ltd Cell population analysis
EP3264989B1 (en) * 2015-03-06 2023-12-20 Micromass UK Limited Spectrometric analysis
GB2554206B (en) 2015-03-06 2021-03-24 Micromass Ltd Spectrometric analysis of microbes
EP3265822B1 (en) 2015-03-06 2021-04-28 Micromass UK Limited Tissue analysis by mass spectrometry or ion mobility spectrometry
JP6421742B2 (ja) 2015-11-27 2018-11-14 株式会社デンソー 車両制御装置
WO2017178833A1 (en) 2016-04-14 2017-10-19 Micromass Uk Limited Spectrometric analysis of plants
CN121534089A (zh) 2016-05-23 2026-02-17 加州理工学院 调节肠微生物群来治疗神经退行性病症
CN107064340A (zh) * 2017-03-13 2017-08-18 瀚盟测试科技(天津)有限公司 一种检测茶叶中gaba含量的方法
WO2018213204A1 (en) 2017-05-15 2018-11-22 Axial Biotherapeutics, Inc. Inhibitors of microbially induced amyloid
GB201802116D0 (en) 2018-02-09 2018-03-28 Univ Warwick Methods for diagnosing an autistic spectrum disorder
CN109030665A (zh) * 2018-10-08 2018-12-18 黑龙江大学 亲水性液相色谱串联质谱法测定红甜菜中甜菜碱含量的检测方法
US12474327B2 (en) 2018-11-06 2025-11-18 Stalicla Sa Metabolic profiling for the diagnosis of a subset of idiopathic autism spectrum disorder patients, ADS Phenotype 1
EP4012414A1 (en) 2020-12-11 2022-06-15 Stalicla S.A. Diagnosis of autism spectrum disorder phenotype 1
CN113960200B (zh) * 2021-10-19 2023-06-20 首都医科大学附属北京儿童医院 代谢标志物在诊断儿童adhd合并抽动障碍中的应用
CN114705775B (zh) * 2022-03-31 2023-09-12 广东省结核病控制中心 一种肺结核评价的血清代谢标志物及其应用
CN115326953A (zh) * 2022-08-02 2022-11-11 云谱康(大连)生物科技有限公司 一种代谢物组合及应用和检测试剂盒与使用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686311A (en) * 1995-06-23 1997-11-11 The Children's Mercy Hospital Diagnosis of autism and treatment therefor
CA2273683A1 (en) * 1998-06-15 1999-12-15 Ortho-Clinical Diagnostics, Inc. Diagnostic markers for human disorders
JP2006526140A (ja) 2002-12-24 2006-11-16 バイオサイト インコーポレイテッド 鑑別診断のためのマーカーおよびその使用方法
GB0504096D0 (en) * 2005-02-28 2005-04-06 Tipogen As Method
WO2006121952A2 (en) 2005-05-05 2006-11-16 The Regents Of The University Of California Diagnostic biomarkers for neurodevelopmental disorders
DK2013619T3 (en) * 2006-04-10 2017-12-04 Wisconsin Alumni Res Found METHODS FOR USING HUMAN EMBYO STEM CELLS FOR EVALUATION OF THE PHARMACEUTICAL SUBSTANCE AND OTHER CHEMICALS
EP2052255A2 (en) 2006-08-18 2009-04-29 Huntington Medical Research Institutes Methods of determining levels of free amino acids and dipeptides and diagnosing alzheimer's diseases
JP5306345B2 (ja) * 2007-07-26 2013-10-02 フェノメノーム ディスカバリーズ インク 自閉症スペクトラム障害の診断、リスク評価、及びモニタリングを行うための方法
US20100248235A1 (en) * 2007-10-04 2010-09-30 Scherer Stephen W Biomarkers for autism spectrum disorders
WO2009151967A1 (en) * 2008-05-28 2009-12-17 Georgia Tech Research Corporation Metabolic biomarkers for ovarian cancer and methods of use thereof

Similar Documents

Publication Publication Date Title
JP2013525801A5 (2)
CA2797787A1 (en) Metabolic biomarkers of autism
Muthubharathi et al. Metabolomics: small molecules that matter more
Chandler et al. Metabolic pathways of lung inflammation revealed by high-resolution metabolomics (HRM) of H1N1 influenza virus infection in mice
Wang et al. Integration of lipidomics and metabolomics for in-depth understanding of cellular mechanism and disease progression
Zhu et al. Single-neuron identification of chemical constituents, physiological changes, and metabolism using mass spectrometry
Uřinovská et al. Liquid chromatography–tandem mass spectrometry method for determination of five antidepressants and four atypical antipsychotics and their main metabolites in human serum
EP3019624B1 (en) Biomarkers of autism spectrum disorder
Puchades-Carrasco et al. Metabolomics in pharmaceutical research and development
Zhou et al. Comprehensive metabolomic and proteomic analyses reveal candidate biomarkers and related metabolic networks in atrial fibrillation
JP2009528517A5 (2)
Xu et al. Metabolomics: a novel approach to identify potential diagnostic biomarkers and pathogenesis in Alzheimer’s disease
Saheb Sharif-Askari et al. Saliva metabolomic profile of COVID-19 patients associates with disease severity
CN105738626B (zh) 一种新的血清代谢物的组合及其作为肝癌诊断标志物的用途
WO2017082103A1 (ja) うつ病診断用バイオマーカー及びその使用
Laila et al. Role of proteomics in the discovery of autism biomarkers
US20240361326A1 (en) Exosomal lipids and metabolites for the early detection of hepatocellular carcinoma
Quintero et al. Metabolomic biomarkers in mental disorders: bipolar disorder and schizophrenia
Mill et al. Recent advances in understanding of Alzheimer’s disease progression through mass spectrometry-based metabolomics
Quanico et al. Parafilm-assisted microdissection: a sampling method for mass spectrometry-based identification of differentially expressed prostate cancer protein biomarkers
CN116678974A (zh) 一种阿尔茨海默症血浆代谢标志物的筛选方法、血浆代谢标志物及应用
Bonomo et al. Metabolomics markers in Neurology: current knowledge and future perspectives for therapeutic targeting
CN111693624A (zh) 一种与儿童多发性抽动症诊断相关的血浆代谢标志物及其应用
CN112305121B (zh) 代谢标志物在动脉粥样硬化性脑梗死中的应用
WO2015168426A1 (en) Metabolic and genetic biomarkers for memory loss